Clinical trials
Phase 2/3 Lung Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
49 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2002 | 2 |
| 2004 | 1 |
| 2005 | 5 |
| 2006 | 2 |
| 2007 | 2 |
| 2009 | 1 |
| 2011 | 6 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2018 | 6 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Unknown status | 12 |
| Recruiting | 9 |
| Terminated | 9 |
| Active, not recruiting | 5 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 3 |
| Bristol-Myers Squibb | 2 |
| NCIC Clinical Trials Group | 2 |
| SWOG Cancer Research Network | 2 |
| Second Affiliated Hospital of Guangzhou Medical University | 2 |
| AHS Cancer Control Alberta | 1 |
| Alpha Biopharma (Jiangsu) Co., Ltd. | 1 |
| Auron Healthcare GmbH | 1 |
| BioNTech SE | 1 |
| Bioven Sdn. Bhd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Neoplasms | 49 |
| Carcinoma, Non-Small-Cell Lung | 21 |
| Prostatic Neoplasms | 5 |
| Breast Neoplasms | 4 |
| Colorectal Neoplasms | 4 |
| Ovarian Neoplasms | 4 |
| Adenocarcinoma of Lung | 3 |
| Brain Neoplasms | 3 |
| Esophageal Neoplasms | 3 |
| Head and Neck Neoplasms | 3 |
Trials
Showing 1 to 25 of 49. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.